FOXO1 and hepatocellular carcinoma: (102) suggested that the HBV X protein (HBX)-K130M/V131I double-mutant variant could promote HCC progression by activating the AKT/FOXO1 signaling pathway and inducing strong inflammation in the liver via arachidonic acid metabolism.